The BEAMER project has developed a model named “B-COMPASS: BEAMER-COmputational Model for Patient Adherence and Support Solutions”, to understand and address non-adherent behaviour.
B-COMPASS identifies the patients’ needs and preferences, with the intention of supporting their adherence to treatment within the heterogeneity of the different disease-areas and healthcare contexts.
Disease-agnostic in nature, B-COMPASS will help to define the problem of non-adherence and provide guidance for healthcare stakeholders as they develop and implement cost-effective digital tools and solutions.
Interested in discovering how this model could contribute to better patient outcomes and reduced health system expenses? Keep on reading below!
BEAMER provides the model and patient understanding which will be a foundation for stakeholders to design effective solutions.
Profile | Benefits | Outcomes |
---|---|---|
You are a patient |
| B-COMPASS will help you take control of your health with confidence. Through personal support, clear guidance and encouragement to stick to your treatment, your health journey will feel meaningful, helping you achieve a better quality of life. |
You are a healthcare professional |
| B-COMPASS will aim to improve adherence to treatment, leading to better patient outcomes and reduce unnecessary hospital visits. You will gain a deeper understanding of your patients, who needs your attention/support the most and provide the right type and level of support at the right time. |
You are a healthcare manager |
| B-COMPASS will help you focus your team on patients who need the most support, reducing costs and enhancing care while easing the strain on the healthcare system. You will improve efficiency and outcomes by using insights to engage patients and allocate resources more effectively. |
You are from the pharma industry – clinical teams |
| B-COMPASS will help you design more effective clinical trials and engaging patient support programs by understanding the factors that influence patient behaviour, ensuring a balanced, representative population, and minimising study dropouts and protocol deviations. This leads to more accurate and better results and lower R&D costs. |
You are from the pharma industry – commercial teams |
| With B-COMPASS, you can offer products that perform better in the real world because of the accompanying, personalized patient support programs. This will increase the value of treatment and increase treatment persistence. |
You are a regulator |
| With B-COMPASS, regulators will ensure that drugs and devices perform effectively in the real world, leading to better health outcomes, reduced societal impact, and more informed regulatory decisions. |
You are a policy maker |
| With B-COMPASS, policymakers will advance health equity, optimise public health outcomes, and ensure the efficient allocation of healthcare resources, contributing to a sustainable and impactful healthcare system. |
You are a payer |
| With B-COMPASS, payers will ensure that drugs and devices deliver better value for money, improve cost-efficiency in real-world settings, and reduce the broader societal and economic impacts of poor health, aligning with value-based healthcare principles. |
B-COMPASS will help you take control of your health with confidence. Through personal support, clear guidance and encouragement to stick to your treatment, your health journey will feel meaningful, helping you achieve a better quality of life.
B-COMPASS will aim to improve adherence to treatment, leading to better patient outcomes and reduce unnecessary hospital visits. You will gain a deeper understanding of your patients, who needs your attention/support the most and provide the right type and level of support at the right time.
B-COMPASS will help you focus your team on patients who need the most support, reducing costs and enhancing care while easing the strain on the healthcare system. You will improve efficiency and outcomes by using insights to engage patients and allocate resources more effectively.
B-COMPASS will help you design more effective clinical trials and engaging patient support programs by understanding the factors that influence patient behaviour, ensuring a balanced, representative population, and minimising study dropouts and protocol deviations. This leads to more accurate and better results and lower R&D costs.
With B-COMPASS, you can offer products that perform better in the real world because of the accompanying, personalized patient support programs. This will increase the value of treatment and increase treatment persistence.
With B-COMPASS, regulators will ensure that drugs and devices perform effectively in the real world, leading to better health outcomes, reduced societal impact, and more informed regulatory decisions.
With B-COMPASS, policymakers will advance health equity, optimise public health outcomes, and ensure the efficient allocation of healthcare resources, contributing to a sustainable and impactful healthcare system.
With B-COMPASS, payers will ensure that drugs and devices deliver better value for money, improve cost-efficiency in real-world settings, and reduce the broader societal and economic impacts of poor health, aligning with value-based healthcare principles.
To test the effectiveness of B-COMPASS, validation studies are being conducted all throughout 2025.
These will assess its performance in six therapeutic areas (cardiovascular, endocrinology, immunology, neurology, oncology and rare diseases), with patients and healthcare professionals. In total, eight different pilot sites in six countries will collect data, which will be used to evaluate the B-COMPASS’s effectiveness in supporting patients and improving adherence.
Akershus University Hospital, Norway
Cardiovascular
APDP Diabetes, Portugal
Endocrinology
Foundation for Biomedical Research and Innovation in Primary Care, Spain
Cardiovascular, Endocrinology, Neurology
Foundation for Biomedical Research of University Pediatric Hospital Niño Jesús of Madrid, Spain
Immunology
Multiple Sclerosis Society Foundation, Italy
Neurology
MEDIDA, Portugal
Cardiovascular, endocrinology, neurology
Heinrich-Heine-University, Düsseldorf, Germany
Immunology, oncology, rare diseases
World Duchenne Organization, the Netherlands
Rare diseases
To test the effectiveness of B-COMPASS, validation studies are being conducted all throughout 2025.
These will assess its performance in six therapeutic areas (cardiovascular, endocrinology, immunology, neurology, oncology and rare diseases), with patients and healthcare professionals. In total, eight different pilot sites in six countries will collect data, which will be used to evaluate the B-COMPASS’s effectiveness in supporting patients and improving adherence.
The BEAMER model becomes more applicable in real-world settings when people like you share your perspective and knowledge today.
Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.
Disclaimer:
Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
The primary aim of the end user personas is to support the creation of materials to support the implementation of the BEAMER model framework and to help define requirements for the elements of the BEAMER model framework. Hence, healthcare professionals (HCPs) represent the primary envisaged end user group of the BEAMER model framework and the associated Adherence Intelligence Visualisation Platform (AIVP)
It is one learning from the joint design process that the job titles of healthcare professional team members do not necessarily predict the roles they would play within the change management process for implementing BEAMER and installing it as a standard model within healthcare. Additionally, the role and responsibilities of certain job titles, for example nurse, varies across different healthcare systems and would affect how they interact with the BEAMER model outputs and the access they would be permitted and so it would not be helpful to include these job titles: The four personas represent role-independent archetypes within the group of HCPs. They encompass a Managerial HCP Persona, an Implementer HCP Persona, a Support HCP Persona, and a Established HCP Persona.
These healthcare professional personas may be further tailored to specific healthcare settings depending on the needs of the individual pilot sites. Thus, adapted or spin-off versions of these original personas may be considered. The persona displays include a summarising statement, goals, challenges, experience, and needs to enhance the accessibility and usability of the model while minimising user burden.
Patient organisations are considered potential users of the model outputs. Consequently, personas were designed for these groups to assure that the implementation materials may also support their needs in the longer term, thus fostering sustainability of the project outputs.
The identified focus areas within this persona are goals, needs, skills and tools, along with potential challenges anticipated during the implementation process. The persona emphasises awareness-raising, capacity building, education, peer support provision, and the promotion of research and development in therapeutic care.
The patient organisation persona serves as a theoretical framework representing how patient organisations could benefit from and include the BEAMER model framework in their therapy and care related as well as their organisational work. This persona comprises the needs, goals, challenges and necessary tools, facilitating preparation and implementation of the model and optimising the user experience of patient organisations as end users of the BEAMER model framework. It can be used as a guide to identify potential obstacles and understand the prerequisites for a patient organisation to successfully adopt and integrate the BEAMER model framework.
“In implementing the BEAMER model, we want to be able to respond to the different needs of our patients to ensure their adherence, build a supportive community and improve outcomes.”